CLEAR – 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes

Uveal Melanoma is a rare cancer with approximately 3,000 cases diagnosed in the US every year. Nearly half of those diagnosed experience spread of their cancer outside the eye. The DecisionDx-UM gene expression test classifies an individual’s tumor as low risk (class 1) or high risk (class 2) of spreading. This study is being done to collect information about how physicians are using the DecisionDx-UM results to design individual treatment plans. It will also track outcomes for the uveal melanoma population that received DecisionDx-UM testing.